Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Retail Pharmacy and Hospital Pharmacy are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors key companies include Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation and Jacobio Pharmaceuticals, etc. Amgen, Mirati Therapeutics, Novartis are top 3 players and held % share in total in 2022.
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors can be divided into Direct Inhibitors and Signal transduction inhibitors, etc. Direct Inhibitors is the mainstream product in the market, accounting for % share globally in 2022.
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is widely used in various fields, such as Retail Pharmacy, Hospital Pharmacy and Online Pharmacy,, etc. Retail Pharmacy provides greatest supports to the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry development. In 2022, global % share of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors went into Retail Pharmacy filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Amgen
Mirati Therapeutics
Novartis
Genentech
Verastem Oncology
Revolution Medicines
Cardiff Oncology
Immuneering Corporation
Jacobio Pharmaceuticals
BridgeBio Pharma
Deciphera Pharmaceuticals
Elicio Therapeutics
InventisBio
Gritstone Bio
D3 Bio
Segment by Type
Direct Inhibitors
Signal transduction inhibitors
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors introduction, etc. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
North America, Europe and Asia Pacific are the key regions for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors key companies include Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation and Jacobio Pharmaceuticals, etc. Amgen, Mirati Therapeutics, Novartis are top 3 players and held % share in total in 2022.
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors can be divided into Direct Inhibitors and Signal transduction inhibitors, etc. Direct Inhibitors is the mainstream product in the market, accounting for % share globally in 2022.
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is widely used in various fields, such as Retail Pharmacy, Hospital Pharmacy and Online Pharmacy,, etc. Retail Pharmacy provides greatest supports to the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry development. In 2022, global % share of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors went into Retail Pharmacy filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Amgen
Mirati Therapeutics
Novartis
Genentech
Verastem Oncology
Revolution Medicines
Cardiff Oncology
Immuneering Corporation
Jacobio Pharmaceuticals
BridgeBio Pharma
Deciphera Pharmaceuticals
Elicio Therapeutics
InventisBio
Gritstone Bio
D3 Bio
Segment by Type
Direct Inhibitors
Signal transduction inhibitors
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors introduction, etc. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices